文献速递心力衰竭与心肌病

高精度RNA核酸酶CRISPR-Cas13d等位基因特异性抑制变异MHC预防肥厚型心肌病

Allele-Specific Suppression of Variant MHC With High-Precision RNA Nuclease CRISPR-Cas13d Prevents Hypertrophic Cardiomyopathy.
PubMed 文献 · Circulation · 2024-05-16

该研究开发了高精度Cas13d变体(hpCas13d),可特异性切割携带单核苷酸变异的MYH7等位基因RNA,而不影响野生型等位基因。在两种携带不同MYH7变异的HCM小鼠模型中,通过AAV9递送hpCas13d特异性抑制突变等位基因并预防心脏肥大。大规模筛选显示hpCas13d可解决45种人类MYH7致病性SNV。

要点

  • hpCas13d通过3个氨基酸替换实现高精度,最小化旁切RNA酶活性。
  • 在两种HCM小鼠模型中,AAV9递送hpCas13d特异性抑制突变等位基因并预防心脏肥大。
  • hpCas13d可解决45种人类MYH7等位基因致病性SNV。

核心结论

  • 高精度Cas13d变体可等位基因特异性抑制MYH7变异RNA,在HCM小鼠模型中预防心脏肥大。

研究设计与样本

  • 研究开发了敏感等位基因点突变报告系统筛选Cas13d诱变变体,基于同源结构合理设计系列Cas13d变体。
  • 通过多种体外实验验证hpCas13d的高精度和低旁切活性。
  • 构建了2种携带不同MYH7 SNV的HCM小鼠模型,使用AAV9将hpCas13d特异性递送至心肌细胞。
  • 进行大规模文库筛选评估hpCas13d解决45种人类MYH7等位基因致病性SNV的效力。

主要发现

  • 野生型Cas13d无法区分并特异性切割携带SNV的杂合MYH7等位基因。
  • hpCas13d具有3个氨基酸替换,最小化旁切RNA酶活性,能够解决多种导致HCM的人类MYH7病理序列变异。
  • 在2种由不同人类MYH7类似序列变异导致的HCM模型中,体内应用hpCas13d特异性抑制了变异等位基因并预防了心脏肥大。

临床怎么用

  • 本研究为遗传性心肌病的治疗提供了高精度CRISPR-Cas核酸酶的新策略,但尚处于动物实验阶段,临床转化需进一步验证。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Familial hypertrophic cardiomyopathy has severe clinical complications of heart failure, arrhythmia, and sudden cardiac death. Heterozygous single nucleotide variants (SNVs) of sarcomere genes such as MYH7 are the leading cause of this type of disease. CRISPR-Cas13 (clustered regularly interspaced short palindromic repeats and their associated protein 13) is an emerging gene therapy approach for treating genetic disorders, but its therapeutic potential in genetic cardiomyopathy remains unexplored. METHODS: We developed a sensitive allelic point mutation reporter system to screen the mutagenic variants of Cas13d. On the basis of Cas13d homology structure, we rationally designed a series of Cas13d variants and obtained a high-precision Cas13d variant (hpCas13d) that specifically cleaves the MYH7 variant RNAs containing 1 allelic SNV. We validated the high precision and low collateral cleavage activity of hpCas13d through various in vitro assays. We generated 2 HCM mouse models bearing distinct MYH7 SNVs and used adenovirus-associated virus serotype 9 to deliver hpCas13d specifically to the cardiomyocytes. We performed a large-scale library screening to assess the potency of hpCas13d in resolving 45 human MYH7 allelic pathogenic SNVs. RESULTS: Wild-type Cas13d cannot distinguish and specifically cleave the heterozygous MYH7 allele with SNV. hpCas13d, with 3 amino acid substitutions, had minimized collateral RNase activity and was able to resolve various human MYH7 pathological sequence variations that cause hypertrophic cardiomyopathy. In vivo application of hpCas13d to 2 hypertrophic cardiomyopathy models caused by distinct human MYH7 analogous sequence variations specifically suppressed the altered allele and prevented cardiac hypertrophy. CONCLUSIONS: Our study unveils the great potential of CRISPR-Cas nucleases with high precision in treating inheritable cardiomyopathy and opens a new avenue for therapeutic management of inherited cardiac diseases.

来源:Circulation,查看原文。版权归原作者所有。

引用

  1. Yang P, Lou Y, Geng Z, et al. Allele-Specific Suppression of Variant MHC With High-Precision RNA Nuclease CRISPR-Cas13d Prevents Hypertrophic Cardiomyopathy. Circulation. 2024. PMID: 38752340. doi:10.1161/CIRCULATIONAHA.123.067890

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。